Linezolid resistance in a clinical isolate of Staphylococcus aureus.
The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
Tsiodras
S
S
Gold
H S
HS
Sakoulas
G
G
Eliopoulos
G M
GM
Wennersten
C
C
Venkataraman
L
L
Moellering
R C
RC
Ferraro
M J
MJ
D000081:Acetamides / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy / Q000382:microbiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D011500:Protein Synthesis Inhibitors; D000069349:Linezolid